Damora Therapeutics, Inc. earns about -372% on invested capital, and has bought back 95% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below. Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | −$51.8M1 | −$61.6M2 | −$38.3M3 | −$21.4M4 | −$209.8M4 |
| Operating cash flow | −$52.3M5 | −$42.9M6 | −$36.9M7 | −$18.6M8 | −$6.73M8 |
| Capital expenditure | $223,0009 | $196,00010 | — | — | — |
| Free cash flow (derived) | −$52.5M5,9 | −$43.1M6,10 | — | — | — |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $62.6M11 | $32.8M12 | $21.5M13 | $14.2M14 | $257.6M14 |
| Diluted shares | 25.3M | 25.4M | 1.1M | 1.2M | 1.4M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.
10 shares is a claim on $1,763.6 of net worth that earned you −$1,539.53 last year.
It earned an average -372% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is down 95% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
This page is free, and so is every other company on MeritValue.
Connect the MeritValue MCP server to Claude or another MCP client, ask about Damora Therapeutics, Inc., and get these exact figures with their filing receipts — not an improvised DCF.
Get a free key →Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.
See pricing →Follow DMRA and keep your own price beside the value. The same engine, with the same receipts.
MeritValue on the App Store →- 10-K filed 2023-03-09 · period ending 2021-12-31 · accession 0000950170-23-006807 (NetIncomeLoss)
- 10-K filed 2024-03-08 · period ending 2022-12-31 · accession 0000950170-24-028610 (NetIncomeLoss)
- 10-K filed 2025-03-19 · period ending 2023-12-31 · accession 0000950170-25-041981 (NetIncomeLoss)
- 10-K filed 2026-03-19 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-115922 (NetIncomeLoss)
- 10-K filed 2023-03-09 · period ending 2021-12-31 · accession 0000950170-23-006807 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2024-03-08 · period ending 2022-12-31 · accession 0000950170-24-028610 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2025-03-19 · period ending 2023-12-31 · accession 0000950170-25-041981 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2026-03-19 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-115922 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2023-03-09 · period ending 2021-12-31 · accession 0000950170-23-006807 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K filed 2024-03-08 · period ending 2022-12-31 · accession 0000950170-24-028610 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K filed 2023-03-09 · period ending 2021-12-31 · accession 0000950170-23-006807 (CashAndCashEquivalentsAtCarryingValue)
- 10-K filed 2024-03-08 · period ending 2022-12-31 · accession 0000950170-24-028610 (CashAndCashEquivalentsAtCarryingValue)
- 10-K filed 2025-03-19 · period ending 2023-12-31 · accession 0000950170-25-041981 (CashAndCashEquivalentsAtCarryingValue)
- 10-K filed 2026-03-19 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-115922 (CashAndCashEquivalentsAtCarryingValue)